Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions

Gastro-esophageal adenocarcinomas (GEA) represent a severe global health burden and despite improvements in the multimodality treatment of these malignancies the prognosis of patients remains poor. HER2 overexpression/amplification has been the first predictive biomarker approved in clinical practic...

Descripción completa

Detalles Bibliográficos
Autores principales: Battaglin, Francesca, Naseem, Madiha, Puccini, Alberto, Lenz, Heinz-Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042434/
https://www.ncbi.nlm.nih.gov/pubmed/30008616
http://dx.doi.org/10.1186/s12935-018-0594-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042434/
https://www.ncbi.nlm.nih.gov/pubmed/30008616
http://dx.doi.org/10.1186/s12935-018-0594-z

Ejemplares similares